Among US veterans (mean age 60) with T2 diabetes who received semaglutide (Ozempic) there was a risk of 0.3% in the first 2 years of NAION, a serious vision loss event, that exceeded SGLT-2 inhibitor drugs (graph) @JAMAOphth